Thermo Fisher Scientific Remaining performance obligations
Remaining performance obligations at Thermo Fisher Scientific came to $29.9B at 26 Sep 2026, up 12.9% from a year earlier.
As Thermo Fisher Scientific reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Oct 2026.
By quarter
| Period ending | Remaining performance obligations | Change on a year | Filed |
|---|---|---|---|
| 26 Sep 2026 | $29.9B | up 12.9% | 30 Oct 2026 |
| 27 Jun 2026 | $29.7B | up 18.6% | 31 Jul 2026 |
| 28 Mar 2026 | $29.4B | up 19.8% | 1 May 2026 |
| 31 Dec 2025 | $27.9B | up 13.4% | 26 Feb 2026 |
| 27 Sep 2025 | $26.5B | up 4.6% | 31 Oct 2025 |
| 28 Jun 2025 | $25.0B | down 3.4% | 1 Aug 2025 |
| 29 Mar 2025 | $24.5B | down 6.9% | 2 May 2025 |
| 31 Dec 2024 | $24.6B | down 8.6% | 20 Feb 2025 |
| 28 Sep 2024 | $25.3B | down 5.6% | 1 Nov 2024 |
| 29 Jun 2024 | $25.9B | up 2.1% | 2 Aug 2024 |
| 30 Mar 2024 | $26.4B | up 2.2% | 3 May 2024 |
| 31 Dec 2023 | $26.9B | down 0.2% | 22 Feb 2024 |
| 30 Sep 2023 | $26.8B | up 0.8% | 3 Nov 2023 |
| 1 Jul 2023 | $25.4B | down 8.3% | 4 Aug 2023 |
| 1 Apr 2023 | $25.8B | down 10.5% | 5 May 2023 |
| 31 Dec 2022 | $27.0B | down 4.7% | 23 Feb 2023 |
| 1 Oct 2022 | $26.6B | up 83.6% | 4 Nov 2022 |
| 2 Jul 2022 | $27.7B | up 104.3% | 5 Aug 2022 |
| 2 Apr 2022 | $28.8B | up 117.0% | 6 May 2022 |
| 31 Dec 2021 | $28.3B | up 120.9% | 24 Feb 2022 |
| 2 Oct 2021 | $14.5B | up 29.8% | 4 Nov 2021 |
| 3 Jul 2021 | $13.6B | up 35.7% | 6 Aug 2021 |
| 3 Apr 2021 | $13.3B | up 59.0% | 7 May 2021 |
| 31 Dec 2020 | $12.8B | up 64.9% | 25 Feb 2021 |
| 26 Sep 2020 | $11.2B | up 65.1% | 30 Oct 2020 |
| 27 Jun 2020 | $10.0B | up 41.3% | 31 Jul 2020 |
| 28 Mar 2020 | $8.4B | up 50.1% | 1 May 2020 |
| 31 Dec 2019 | $7.8B | up 52.7% | 26 Feb 2020 |
| 28 Sep 2019 | $6.8B | up 32.0% | 1 Nov 2019 |
| 29 Jun 2019 | $7.1B | up 38.1% | 2 Aug 2019 |
| 30 Mar 2019 | $5.6B | up 12.8% | 3 May 2019 |
| 31 Dec 2018 | $5.1B | — | 27 Feb 2019 |
| 29 Sep 2018 | $5.1B | — | 2 Nov 2018 |
| 30 Jun 2018 | $5.1B | — | 3 Aug 2018 |
| 31 Mar 2018 | $4.9B | — | 4 May 2018 |
Definition
Revenue under signed contracts that the company has not yet recognised: deferred revenue plus amounts it will invoice and recognise later (ASC 606). Stated at each balance-sheet date. Companies may leave out contracts of a year or less. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Thermo Fisher Scientific: Organic revenue (change on a year) · Product revenues · Service revenues · Consumables revenue · Instruments revenue · Clinical research revenue · Research and safety market channel revenue · Pharma services revenue · Biosciences revenue · BioProduction revenue · Chromatography and mass spectrometry revenue · Electron microscopy revenue · Genetic sciences revenue · Laboratory products revenue · Healthcare market channel revenue · Chemical analysis revenue · Clinical diagnostics revenue · ImmunoDiagnostics revenue · Transplant diagnostics revenue · Microbiology revenue · Laboratory Products and Biopharma Services revenue · Life Sciences Solutions revenue · Analytical Instruments revenue · Specialty Diagnostics revenue · financial statements
Every KPI and segment of TMO, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.